A clinical-stage biotech sorting blood one cell at a time, in pursuit of a cleaner kind of cure.
On any given Tuesday in Menlo Park, a refrigerated truck pulls into 3475 Edison Way carrying a courier bag of donor blood. Inside the building, a machine the size of a small refrigerator begins reading the bag the way a librarian reads a card catalog - one cell at a time. Out the other end comes something that did not exist that morning: a precisely measured cocktail of stem cells, conventional T cells, and regulatory T cells, bound for a patient who, somewhere else in America, is having the worst week of their life.
This is Orca Bio. They are not interested in being a household name. They are interested in being the reason a household still has its mother in it.
Allogeneic stem cell transplant has been, for decades, the closest thing oncology has to a cure for the worst blood cancers. It is also one of medicine's least gentle gifts. A donor's immune system, once transferred, often mistakes the patient for a foreign country and declares war. Doctors call this graft-versus-host disease. Patients call it - if they survive it - the part nobody warned them about loudly enough.
The conventional answer has been to suppress the immune system into silence and hope for the best. Sometimes the cancer comes back. Sometimes the immune system never quite recovers. Sometimes both. The math has been bad for a long time, and the field has, with a kind of weary politeness, accepted it.
In 2016, Ivan Dimov, Nate Fernhoff, and Jeroen Bekaert met at Stanford and decided the math could be better. Their wager was unfashionably specific: if you could sort the cells in a donor's blood with enough precision - separating the cells that drive disease relapse from the cells that drive recovery from the cells that drive that war we mentioned - you could rebuild an immune system instead of replacing one. You would not need to silence anything. You would need to compose.
They called the company Orca Bio. The name is meant to suggest something patient, intelligent, and quietly capable of moving through deep water. The branding people earned their fee.
The first version of the technology came out of Dimov's lab and a long argument with a chip designer about whether you could read a single cell faster than you could lose it. You could, it turned out. Whether you could do it at the scale of a human patient was the next question. Whether you could do it at the scale of a launched product was the question after that.
A short, suspiciously linear story of a very nonlinear science.
Founded at Stanford by Dimov, Fernhoff, and Bekaert.
First-in-human dosing of Orca-T at Stanford Medicine.
Series D and the move into the Edison Way facility.
Phase 3 Precision-T trial opens across U.S. transplant centers.
Phase 3 enrollment completes at 187 patients - 13 over target.
BLA accepted for FDA priority review. $250M Series F closes.
PDUFA action date for Orca-T set for April 6.
Orca-T is the lead candidate, currently being studied for acute myeloid leukemia, acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes. The product is not a small molecule. It is not even a single biologic. It is a precisely composed mixture: purified stem cells, conventional T cells, and a population of regulatory T cells that the manufacturing platform isolates from the donor and adds back in the right proportion. The regulatory T cells are the diplomats. They tell the rest of the immune system to attack the cancer but not the patient.
Then there is Orca-Q, designed for situations where a fully matched donor is not available - which is to say, for many of the patients who currently are quietly told that there is nothing else to try. Behind both candidates is the platform itself: a cell-sorting and engineering workflow that the company has spent nearly a decade making boring enough to ship.
Phase 3. BLA accepted. The lead in hematologic malignancies. The reason there is a PDUFA date on the calendar.
Next-generation. Designed to work when the donor is not a perfect match - which is most of the time.
Single-cell sorting at clinical scale. The unsexy thing that makes the other two possible.
In the Phase 3 Precision-T study, Orca-T was associated with significantly better chronic GvHD-free survival than the conventional standard of care, allogeneic hematopoietic stem cell transplantation with tacrolimus and methotrexate. The trial enrolled 187 patients - past its target of 174 - across major U.S. transplant centers. The BLA, accepted for FDA priority review, set up an April 6, 2026 PDUFA target action date. The FDA later extended the review timeline, which is the regulatory equivalent of telling you the kitchen needs five more minutes.
Orca Bio's stated mission is to redefine what is possible for patients by transforming the field of curative allogeneic cell therapy. In practice, that means a few thousand people a year in the United States who today face an allogeneic transplant could face a procedure that asks less of their body and gives more back. It also means that the same platform - the same expensive, finicky, quietly impressive cell-sorting machinery - is in principle pointed at autoimmune disease next. Lupus, scleroderma, type 1 diabetes: a long list of conditions where the immune system has lost the thread.
None of which is guaranteed. The FDA may take its time. Reimbursement is its own multi-year argument. Manufacturing cell therapy at commercial scale is famously the part where biotech founders stop sleeping. But Orca has spent nine years de-risking exactly those problems on purpose, which is, in this industry, an unfashionable amount of patience.
Back at Edison Way on a Tuesday, the refrigerated truck pulls out empty. Somewhere downstream, in a hospital you may or may not have heard of, a patient is being prepped for an infusion of cells that, until quite recently, did not exist as a category. They will not see the chip, the courier, the cocktail, or the calendar with the PDUFA date circled in someone's office. They will see a bag, a line, and a nurse. That is the appropriate amount of invisibility for a piece of infrastructure.
Orca Bio's job, if it works, is to keep being invisible. Cures, when they arrive, tend to be boring. The interesting part is the decade before.